Study Title
Study Details
Description:
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Sponsor:
CuriumContacts:
Darcy Denner, Ph.D. (Clinical Trial Director)darcy.denner@curiumpharma.com
Government Study Link:
NCT05204927 - Click here to see study onClinicalTrials.gov
Inclusion
- Males, 18 years or older
- Positive PSMA PET scan
- Proven metastatic castration-resistant prostate cancer
Exclusion
- Previous treatment with chemotherapy in the castration-resistant setting
- Previous treatment with more than one ARAT
- Previous treatment with other radioligand therapy
Publications
Publications Not Yet Provided
Locations
United States
France
Italy